Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Foghorn Therapeutics Inc.

Foghorn Therapeutics is pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. Our proprietary Gene Traffic Control® platform gives us an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing us to identify, validate and potentially drug targets within the system.

Flagship Pioneering

Casdin Capital

Invus

Irving Investors

Happy New Year from all of us at Foghorn! As we kick off 2024, we look forward to the year ahead as we continue to advance our mission to transform patient’s lives by correcting abnormal gene expression. #biotechnology #innovation #oncology

Check out photos of our Foghorn team, who had fun swapping surprises at our end of year holiday party. From all of us at Foghorn, wishing everyone a healthy and happy holiday season! #HappyHolidays

That's a wrap on the 65th Annual American Society of Hematology Meeting! Our team enjoyed coming together with the scientific community to present data and talk about our novel approach to modulating the chromatin regulatory system. Read all of our recent data presentations from #ASH23 and beyond: https://bit.ly/3GJ2vkZ

Martin (Murphy) Hentemann Kathleen Healy Caroline Almon #biotechnology #innovation #TPD

Meet Alexia Kalogeropulou, one of our brilliant scientists at Foghorn. Alexia shares why she loves the collaborative culture that enables us to advance our mission to transform the lives of people living with a wide spectrum of diseases. #LifeAtFoghorn #WomenInSTEM #biotechnology

Join us at the 2nd Annual TPD Assay Development & Screening Summit, where our Head of #DrugDiscovery, Marina Nelen, will be part of a panel to discuss high-throughput screening approaches and applications of assay techniques to degrader triage and profiling. See the agenda: https://ow.ly/J9Bh50QfwVc
#biotechnology #innovation #proteindegradation

We’re looking forward to the 65th American Society of Hematology Annual Meeting and Exposition, where clinical data from the Phase 1 dose-escalation study of FHD-286 in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) will be presented. Learn more: https://ow.ly/wc3q50Qel4h
#ASH23

We know that our people are the key to our success, which is why we embrace a people first culture. Our culture is just one reason that Madeleine Henley was drawn to Foghorn. Learn more about our culture: https://ow.ly/Ca4050Qe2u8 

#LifeAtFoghorn #WomenInSTEM

Happy #Thanksgiving to all! Today, we are especially thankful for the incredible Foghorn team and their unwavering commitment to our mission of transforming lives across a wide spectrum of diseases. #biotechnology #innovation

Last week, we had the pleasure of joining other leading experts in the chromatin and epigenetics field during #Epi2023, where Dave Lahr gave a presentation on our preclinical work during a session on the nucleosome and chromatin remodeling. Find all our recent data presentations here: https://lnkd.in/gUtu9Wfi

#biotechnology #oncology #innovation

Congratulations to this year's recipients of the 2023 Paul Marks Prize for Cancer Research, including our scientific co-founder, Cigall Kadoch! This award underscores the important work being done at Foghorn to address breakdowns in the chromatin regulatory targets to advance novel treatments in cancer and beyond. #oncology #cancerresearch #innovation

Filer	Latest Filing Date	Share-Type	Shares	Market Value	Previously owned	Change
Flagship Pioneering Inc.	2021-05-17	Shares	12.67M	167.04M	12.67M	0
Flagship Pioneering Inc.	2023-08-14	Shares	12.67M	89.23M	12.67M	0
Fmr Llc	2021-05-14	Shares	2.57M	33.20M	2.58M	-7.60K
Artal Group S.A.	2021-05-14	Shares	1.72M	22.68M	1.72M	0
Artal Group S.A.	2023-08-11	Shares	1.72M	12.11M	1.72M	0
Euclidean Capital Llc	2023-08-14	Shares	1.57M	11.08M	1.26M	312.50K
Euclidean Capital Llc	2021-05-17	Shares	1.26M	16.62M	1.26M	0
Cormorant Asset Management, Lp	2021-05-17	Shares	1M	13.18M	1M	0
Monashee Investment Managem...	2021-05-14	Shares	530.58K	6.99M	560.36K	-29.78K
Alphabet Inc.	2022-11-15	Shares	500.90K	6.60M	500.90K	0
Blackrock Inc.	2021-05-07	Shares	432.13K	5.70M	672.20K	-240.08K
Vanguard Group Inc	2021-05-14	Shares	407.33K	5.37M	403.45K	3.88K
Morgan Stanley	2021-05-17	Shares	393.72K	5.19M	42.74K	350.98K
Birchview Capital, Lp	2021-05-14	Shares	314.14K	4.14M	314.14K	0
Deutsche Bank Ag\	2021-05-13	Shares	222.91K	2.94M	5.05K	217.87K
Casdin Capital, Llc	2021-05-17	Shares	216.22K	2.85M	216.22K	0
Millennium Management Llc	2021-05-17	Shares	162.12K	2.14M	214.86K	-52.74K
Geode Capital Management, Llc	2021-05-12	Shares	146.64K	1.93M	132.51K	14.13K
Point72 Asset Management, L.P.	2021-05-17	Shares	109.20K	1.44M	0	109.20K
State Street Corp	2021-07-09	Shares	109.10K	1.44M	101.80K	7.30K
Pictet Asset Management Ltd	2021-05-17	Shares	98.08K	1.29M	99.24K	-1.15K
Northern Trust Corp	2021-05-12	Shares	84.30K	1.11M	88.44K	-4.14K
Suvretta Capital Management...	2021-05-17	Shares	84K	1.11M	258.70K	-174.70K
Octagon Capital Advisors Lp	2021-05-17	Shares	69.13K	911K	0	69.13K
Charles Schwab Investment M...	2021-05-17	Shares	47.60K	628K	45.96K	1.65K
Baker Bros. Advisors Lp	2023-08-14	Shares	45.03K	316.99K	45.03K	0
Board Of Trustees Of The Le...	2021-05-14	Shares	30.66K	404K	30.66K	0
Jpmorgan Chase & Co	2021-05-12	Shares	20.01K	264K	19.64K	372
Bank Of New York Mellon Corp	2021-05-13	Shares	19.44K	256K	18.09K	1.35K
Hsbc Holdings Plc	2021-05-14	Shares	18.74K	251K	18.90K	-158
Victory Capital Management Inc	2021-05-04	Shares	16.19K	213K	93.07K	-76.88K
Nuveen Asset Management, Llc	2021-05-17	Shares	11.81K	239K	0	11.81K
Fiduciary Trust Co	2021-05-19	Shares	10.88K	143K	10.88K	0
California State Teachers R...	2021-05-18	Shares	10.88K	143K	10.88K	0
Bank Of America Corp /De/	2021-05-14	Shares	5.41K	71K	1.65K	3.75K
American International Grou...	2021-05-07	Shares	4.19K	55K	4.18K	11
New York State Common Retir...	2021-05-11	Shares	4.10K	54K	4.10K	0
Wells Fargo & Company/Mn	2021-05-13	Shares	2.25K	30K	3.75K	-1.50K
Ubs Group Ag	2021-05-12	Shares	2.14K	28K	2.25K	-112
Tower Research Capital Llc ...	2021-05-17	Shares	1.97K	26K	438	1.53K
Sunbelt Securities, Inc.	2023-08-16	Shares	1.60K	11.26K	1.60K	0
Royal Bank Of Canada	2021-07-20	Shares	1.28K	17K	372	907
Legal & General Group Plc	2021-05-17	Shares	716	9K	716	0
Capital Analysts, Llc	2021-05-17	Shares	605	8K	0	605
Ameritas Investment Partner...	2021-05-14	Shares	602	8K	602	0
Citigroup Inc	2021-05-13	Shares	477	6K	1.33K	-852
Tfc Financial Management, Inc.	2021-05-03	Shares	280	4K	280	0
Bank Of Montreal /Can/	2021-05-13	Shares	222	3K	1.13K	-908
Visionpoint Advisory Group,...	2023-08-21	Shares	210	1.48K	0	210
Retirement Group, Llc	2021-05-04	Shares	29	0	29	0
Slow Capital, Inc.	2023-08-09	Shares	0	0	655	-655
Woodline Partners Lp	2021-05-17	Shares	0	0	103.04K	-103.04K
Strs Ohio	2021-04-23	Shares	0	0	1.70K	-1.70K
Goldman Sachs Group Inc	2021-05-17	Shares	0	0	10.85K	-10.85K
Tiaa, Fsb	2023-07-31	Shares	0	0	14.47K	-14.47K
Concourse Financial Group S...	2021-05-13	Shares	0	0	0	0
Caas Capital Management Lp	2021-05-17	Shares	0	0	15K	-15K

NASDAQ:FHTX

Foghorn Therapeutics Inc.

Last Close

7.89

30/08 20:00

Market Cap

265.58M

Beta: 2.16

Volume Today

105.65K

Avg: 76.72K

PE Ratio

−1.07

PFCF: −0.97

Institutional trades

Institutional Ownership

Current holdings institutionals